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Summary
Developmental fate decisions are dictated by master transcription factors (TFs) that interact with
cis-regulatory elements to direct transcriptional programs. Certain malignant tumors may also
depend on cellular hierarchies reminiscent of normal development but superimposed on
underlying genetic aberrations. In glioblastoma (GBM), a subset of stem-like tumor-propagating
cells (TPCs) appears to drive tumor progression and underlie therapeutic resistance, yet remain
poorly understood. Here, we identify a core set of neurodevelopmental TFs (POU3F2, SOX2,
SALL2, OLIG2) essential for GBM propagation. These TFs coordinately bind and activate TPC-
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specific regulatory elements, and are sufficient to fully reprogram differentiated GBM cells to
‘induced’ TPCs, recapitulating the epigenetic landscape and phenotype of native TPCs. We
reconstruct a network model that highlights critical interactions and identifies novel therapeutic
targets for eliminating TPCs. Our study establishes the epigenetic basis of a developmental
hierarchy in GBM, provides detailed insight into underlying gene regulatory programs, and
suggests attendant therapeutic strategies.
Keywords
cis-regulatory elements; enhancers; chromatin; epigenetic states; glioblastoma; stem cells; cellular
hierarchy; cellular reprogramming; cancer
Introduction
In mammalian development, stem and progenitor cells differentiate hierarchically to give
rise to germ layers, lineages and specialized cell types. These cell fate decisions are dictated
and sustained by master regulator transcription factors (TFs), chromatin regulators and
associated cellular networks. It is now well established that developmental decisions can be
overridden by artificial induction of combinations of ‘core’ TFs that yield induced
pluripotent stem (iPS) cells or direct lineage conversion (Hanna et al., 2010; Morris and
Daley, 2013; Orkin and Hochedlinger, 2011; Takahashi and Yamanaka, 2006; Vierbuchen
and Wernig, 2011). These TFs bind and activate cis-regulatory elements that modulate
transcription, and thereby direct cell type-specific gene expression programs (Lee and
Young, 2013).
Increasing evidence suggests that certain malignant tumors also depend on a cellular
hierarchy, with privileged sub-populations driving tumor propagation and growth.
Moreover, many TFs that direct developmental decisions can also function as oncogenes by
promoting the re-acquisition of developmental programs required for tumorigenesis (Suva et
al., 2013). For example, the pluripotency and neurodevelopmental factor Sox2 is an essential
driver of stem-like populations in multiple malignancies. Studies of leukemia pioneered the
concept that triggering cellular differentiation can abolish certain malignant programs and
override genetic alterations (Ito et al., 2008; Wang and Dick, 2005). Similarly, iPS
reprogramming experiments have shown that artificially changing cancer cell identity
profoundly alters their properties (Stricker et al., 2013). These findings suggest that
epigenetic circuits superimposed upon genetic mutations determine key features of cancer
cells.
The extent to which unidirectional differentiation hierarchies underlie tumor heterogeneity
remains controversial (Visvader and Lindeman, 2012). For example, recent studies indicate
that stem-like cells in breast cancer and melanoma exist in dynamic equilibrium with
phenotypically distinct populations incapable of tumor propagation (Chaffer et al., 2013;
Roesch et al., 2010). Alternatively, there is evidence supporting more classical hierarchies in
other cancers, particularly in leukemias (Wang and Dick, 2005). In GBM models,
reversibility seems to depend on the differentiation stimulus and time of exposure. Short-
term exposure of GBM stem-like cells to BMP4 is sufficient to abolish their tumor-
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propagating potential, consistent with unidirectional differentiation (Piccirillo et al., 2006).
Serum-triggered differentiation appears to proceed more gradually; short-term exposure can
be reversed (Lee et al., 2006; Natsume et al., 2013), while longer-term exposure fully
abolishes tumor-propagating potential (Janiszewska et al., 2012; Lee et al., 2006; Wakimoto
et al., 2009). A better understanding of the molecular underpinnings that distinguish stem-
like cancer cells and control plasticity within tumors is a critical goal with broad
implications for diagnosis and therapy.
GBM is the most common malignant brain tumor in adults and remains incurable despite
aggressive treatment (Jansen et al., 2010). Genome sequencing and transcriptional profiling
studies have highlighted a large number of genetic events and identified multiple
biologically relevant GBM subtypes, representing a major challenge for targeted therapy
(Sturm et al., 2012; Verhaak et al., 2010). There is strong evidence that differentiation status
significantly impacts GBM cell properties, with stem-like cells likely driving tumor
propagation and therapeutic resistance (Bao et al., 2006; Chen et al., 2012). Although
putative stem-like populations in GBM can be enriched using cell surface markers such as
CD133 (Singh et al., 2004), SSEA-1 (Son et al., 2009), CD44 (Anido et al., 2010), and
integrin alpha 6 (Lathia et al., 2010), the consistency of the various markers and the extent to
which genetic heterogeneity contributes to observed phenotypic differences remains
controversial. A TF code for GBM stem-like cells, analogous to those identified in iPS
reprogramming and direct lineage conversion experiments, could thus provide critical
insights into the epigenetic circuitry underlying GBM pathogenesis.
Here we combine functional genomics and cellular reprogramming to reconstruct the
transcriptional circuitry that governs the developmental hierarchy in human GBM. By
comparing the epigenetic landscapes of stem-like GBM cells against their differentiated
counterparts, we identify four core TFs – POU3F2 (BRN2), SOX2, SALL2 and OLIG2 –
whose induction is sufficient to reprogram differentiated GBM into stem-like cells capable
of in vivo tumor propagation. We use this TF code to identify candidate tumor propagating
cells in primary GBM tumors. Genome-wide binding maps and transcriptional profiles
identify key regulatory targets of the core TFs, including the RCOR2/LSD1 histone
demethylase complex. RCOR2 can substitute for OLIG2 in the reprogramming cocktail and,
moreover, stem-like GBM cells are highly sensitive to LSD1 suppression, thus validating
the regulatory model. Our findings demonstrate a cellular hierarchy in GBM, provide
detailed insight into its transcriptional and epigenetic basis, and propose therapeutic
strategies for eliminating stem-like tumor propagating cells in human GBM.
Results
TF activity and cis-regulatory elements distinguish GBM TPCs
To identify distinguishing features of stem-like GBM cells, we expanded matched pairs of
GBM cultures derived from three different human tumors either as stem-like tumor-
propagating cells (TPCs) grown in serum-free, spherogenic culture, or as differentiated
glioblastoma cells (DGCs) grown as adherent monolayers in serum. The alternate culture
conditions confer GBM cells with distinct functional properties, the key of which is their in
vivo tumor-propagating potential in orthotopic xenotransplantation limiting dilution assays
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(Figure 1A and S1) (Chudnovsky et al., 2014; Janiszewska et al., 2012; Lee et al., 2006).
This functional difference is accompanied by differences in expression of stem cell (CD133,
SSEA-1), astroglial (GFAP), neuronal (beta III tubulin, MAP-2) and oligodendroglial
(GalC) markers (Figure 1B, C and S1), consistent with a modulation of the stemness-
differentiation axis by serum. Orthotopic xenotransplantation of as few as 50 GBM TPCs
leads to formation of tumors that recapitulate major histologic features of GBM (Figure 1D),
while as many as 100,000 DGCs fail to initiate tumor. Importantly, although the stem-like
TPCs are able to differentiate and expand as monolayers when exposed to serum, DGCs will
not expand in serum-free conditions, suggesting that the differentiated state is epigenetically
stable. These functional and phenotypic properties suggest that a transcriptional hierarchy
predicated on distinct epigenetic circuits is critical for the tumor-propagating potential of
GBM cells.
To acquire an epigenetic fingerprint of the respective GBM models, we surveyed cis-
regulatory elements in three matched pairs of TPCs and DGCs established from three human
tumors (Materials and Methods). We specifically mapped histone H3 lysine 27 acetylation
(H3K27ac), which marks promoters and enhancers that are ‘active’ in a given cell state
(Bulger and Groudine, 2011; Creyghton et al., 2010; Ernst et al., 2011; Hon et al., 2009;
Rada-Iglesias et al., 2011; Visel et al., 2009). Unsupervised clustering indicates that the
TPCs share similar regulatory element patterning, but are distinct from the DGCs, which are
also consistent across the patient-derived samples (Figure S1). This suggests that regulatory
element activity in our model correlates more closely with phenotypic state than patient- or
tumor-specific genetic background.
To identify TFs that might direct these alternative cell states, we collated sets of TPC-
specific, DGC-specific and shared regulatory elements, and searched the underlying DNA
sequences for over-represented motifs. TPC-specific elements are strongly enriched for
motifs recognized by helix-loop-helix (HLH) and Sry-related HMG box (SOX) family TFs
(Figure 1E), while DGC-specific elements are instead enriched for AP1/JUN motifs,
consistent with a serum-induced differentiation program (Zhu et al., 2013). We
complemented these motif inferences with RNA-Seq expression data and promoter
H3K27ac signals for TF genes to identify candidate regulators of the TPC state. This
analysis yielded a set of 19 TFs with significantly higher expression in TPCs (Figure 2A–C).
Although we previously identified a set of 90 TFs active in GBM stem-like cells (Rheinbay
et al., 2013), this more restrictive set is limited to TFs that are specifically active in TPCs
and thus candidates for directing their epigenetic state. Notably, 10 of the 19 TFs are HLH
or SOX family members, whose cognate motifs were identified in our unbiased analysis of
TPC-specific regulatory elements.
Derivation of a core TF set sufficient to induce a TPC phenotype
Among the 19 TPC-specific TFs, SOX2, OLIG2 and ASCL1 have been shown to be
necessary for spherogenicity and tumor-propagating potential of stem-like GBM cells
(Gangemi et al., 2009; Mehta et al., 2011; Rheinbay et al., 2013). However, the
hypothesized GBM developmental hierarchy raises the possibility that certain combinations
of TFs might be sufficient to reprogram DGCs into TPCs, thus overriding an epigenetic state
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transition that is irreversible in our model. Notably, several TPC-specific TFs are
components of cocktails that have been used to convert fibroblasts into neurons (Pang et al.,
2011) or neural stem cells (Lujan et al., 2012). We therefore considered whether these
principles of cellular reprogramming could be applied to inter-convert epigenetic states in
GBM.
To test the capacity of individual TFs or TF combinations to reprogram GBM cells, we
cloned all 19 TPC-specific TFs and ectopically expressed them in DGCs. We then
monitored single-cell sphere formation in serum-free conditions, surface marker induction
and tumor-propagation by orthotopic xenotransplantation into severe combined
immunodeficient (SCID) mice. We first introduced each TF individually. Of the 19 TFs,
only SOX1, SOX2 and POU3F2 modestly enhanced spherogenesis, with POU3F2 in
particular yielding ~3% sphere formation (compared to ~0% for empty vector and >10% for
native TPCs; Figure 3A). These TFs also stimulated weak induction of the stem-cell marker
CD133 (Figure 3B). However, orthotopic xenotransplantation of as many of 100,000 DGCs
expressing SOX1, SOX2 or POU3F2 failed to initiate tumors in mice (Table S2).
Reasoning that successful GBM reprogramming might require multiple TFs, we next co-
infected DGCs with POU3F2 in combination with each of the other 18 TPC-specific TFs.
We found that co-infection of POU3F2 with SOX1 or SOX2 significantly increased in vitro
sphere-forming potential and CD133 expression (Figure 3A, B). However, neither 2TF
combination nor the SOX1+SOX2 combination initiated tumors in vivo (Table S2). We thus
resumed stepwise reconstruction experiments by adding a third TF to the most effective pair
(POU3F2+SOX2). Although the addition of SALL2, SOX1, HEY2 or OLIG2 improved our
in vitro results, none of these 3TF combinations were sufficient to initiate tumors in vivo
(Figure 3A–C).
Failure to achieve complete reprogramming with these TF combinations led us to consider
whether TF induction effectively activates TPC-specific regulatory elements, as would be
expected in a successful reprogramming experiment. To test this, we mapped H3K27ac-
marked regulatory elements in DGCs infected with POU3F2 alone, with the top 2TF
combination (POU3F2+SOX2), or with the top 3TF combination
(POU3F2+SOX2+SALL2). Each population gained TPC-specific elements and lost DGC-
specific elements, with the 3TF combination inducing the most prevalent changes (Figure
S2). Yet despite their spherogenic potential and CD133 expression, DGCs expressing the
3TF combination failed to induce a large number of TPC-specific elements. Examination of
the subset of TPC-specific regulatory elements that remain silent in these partially
reprogrammed cells revealed a strong enrichment for HLH motifs (Figure S2), suggesting
that complete reprogramming might require an additional HLH TF.
We therefore supplemented the 3TF combination (POU3F2+SOX2+SALL2) with each
HLH factor in the TPC-specific TF set, namely OLIG1, OLIG2, HEY2, HES6 and ASCL1.
Although none of these additions significantly enhanced in vitro assay performance,
combined induction of POU3F2+SOX2+SALL2+OLIG2 yielded cells capable of tumor
initiation in 100% of animals (Figure 3A–C). This 4TF cocktail appears highly specific as
four TF combinations with any of the other HLH factors failed to initiate tumors. Moreover,
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replacement of SOX2 with SOX1 or omission of any single component from the 4TF set
yielded cells without tumor initiating properties (Table S2).
Tumors initiated by ‘induced’ TPCs (iTPCs) expressing the four TFs show classical features
of high-grade gliomas, including necrosis, atypical cytonuclear features and high mitotic
index (Figure 3D). Secondary sphere cultures derived from these tumors express high levels
of CD133 and display proliferation and self-renewal properties in serial sphere formation
assays, similar to their corresponding TPC lines (Figure 3E–G) (Barrett et al., 2012; Chen et
al., 2010). Similarly, serial xenotransplantation of these secondary cultures into SCID mice
in limiting dilutions indicates that as few as 50 iTPC cells initiate tumors in 50% of animals,
while 500 cells confer tumor initiation in 100% of recipients (Figure 3H). Thus, we have
identified a TF cocktail sufficient to reprogram serum-derived differentiated GBM cells into
stem-like GBM cells capable of unlimited self-renewal and tumor propagation.
To evaluate the generality of the TF cocktail, we tested its ability to reprogram other DGC
models. First, we confirmed that the core TFs were capable of reprogramming a second
serum-derived DGC line from a different patient with different genetic aberrations (Figure
3G, 4A). Second, we tested the effects of the TFs in an alternative differentiation model, in
which TPCs are differentiated in serum-free conditions by addition of BMP4 (Piccirillo et
al., 2006). This treatment caused the cells to adhere and down-regulate the core TFs and
CD133 over a 72 hours period. Re-induction of the core TFs in these differentiated GBM
cells re-established spherogenic potential and CD133 expression over a one-week period
(Figure S3). These data suggest that the core TF circuitry plays a general role in modulating
the GBM differentiation axis. Since the specific GBM models investigated here conform to
the proneural subtype (Figure S1), further study will be needed to evaluate the role of these
TFs in other GBM subtypes (Verhaak et al., 2010).
Core TFs fully reprogram the epigenetic state of induced TPCs
To examine the extent to which the four core TFs reprogram the epigenetic state of GBM
cells, we surveyed regulatory element activity and TF expression in secondary iTPC sphere
cultures. Consistent with their tumor-propagating ability, iTPCs gain H3K27ac at most TPC-
specific elements and lose H3K27ac at the majority of DGC-specific elements (Figure 4A).
Furthermore, 18/19 TPC-specific TFs are up-regulated in the iTPCs, and most acquire
K27ac at their promoter, indicating that their epigenetic landscape closely resembles TPCs
(Figure 4B, C). In contrast, DGCs expressing three TFs fail to reset most TPC-specific and
DGC-specific regulatory elements (Figure S2). Thus, all four core TFs are required to
reprogram the epigenetic landscape of GBM cells, consistent with their requirement for the
functional TPC phenotype.
We also considered the mechanistic basis for the sustained phenotype of iTPCs. Several
lines of evidence suggest that the four core TFs are expressed from their endogenous loci in
the iTPCs, while the exogenously introduced expression vectors are silenced. The
endogenous TF genes contain 3′UTRs that distinguish them from the exogenous versions,
which lack UTRs. RNA-Seq profiles confirm endogenous transcripts with 3′UTRs for
POU3F2, SOX2, SALL2 and OLIG2 in iTPCs, but reveal little or no expression of the
exogenous transcripts (Figure 4D). The endogenous TF loci also gain H3K27ac at putative
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regulatory elements, consistent with their reactivation (Figure 4E). Finally, iTPCs markedly
reduce expression of all four TFs and readily differentiate upon exposure to serum (Figure
4F–H), as is indicative of endogenous regulation. These data suggest that induction of the
core TFs triggers an epigenetic state transition that is subsequently maintained by
endogenous regulatory programs.
Core TFs coordinately expressed in a subset of GBM cells from primary human tumors
To investigate the clinical relevance of our findings, we asked whether the core TFs and
corresponding regulatory elements are active in primary human GBM tumors. First we
sought to identify individual cells within GBM tumors that co-express all four core factors,
postulating that these could represent candidate stem-like TPCs. We performed four-color
immunofluorescence and five-color flow cytometry on freshly resected tumors using
antibodies against POU3F2, SOX2, SALL2, OLIG2 and CD133. We found that SOX2
identifies the largest set of GBM cells, while SALL2 and POU3F2 have more restricted
expression. Image analysis and flow cytometry both identified a small subset of cells in
primary tumors (~2–7%) that coordinately express all four TFs (Figure 5A, B). Remarkably,
more than 50% of the 4TF-positive cells also express CD133, a striking enrichment over
4TF-negative cells, which almost entirely lack this stem cell marker (Figure 5B). Finally, we
also mapped H3K27ac genome-wide in several freshly resected GBM tumors. This bulk
analysis revealed significant enrichment for ~50% of TPC-specific regulatory elements,
suggesting that they are also active in primary tumor cells (Figure 5C). Collectively, these
data suggest that the core TFs, regulatory elements and circuits defined in our TPC model
are active in a subset of primary GBM cells that express the stem cell marker CD133 and
may underlie tumor propagation.
Essential roles for core TFs and their regulatory targets in GBM TPCs
The identification of TPC-like cells in primary GBM tumors prompted us to investigate the
regulatory functions and interactions of the core TFs, reasoning that this might suggest new
therapeutic targets or strategies. First, we confirmed that all four TFs are essential for in
vitro and in vivo TPC phenotypes. Prior studies had established SOX2 and OLIG2 as
essential regulators in this context (Gangemi et al., 2009; Mehta et al., 2011). By performing
shRNA-mediated knock-down in TPCs, we showed that POU3F2 and SALL2 are also
required for sphere formation in vitro and tumor-propagation in vivo (Figure 3I, J and S4).
To identify direct regulatory targets, we next mapped the binding sites of POU3F2, SOX2,
SALL2 and OLIG2 in TPCs using ChIP-Seq with specific antibodies for each factor (Figure
6A and S5). All four TFs preferentially associate with TPC-specific regulatory elements,
and there is significant overlap among their binding sites (Figure 6B and S5). As expected,
POU3F2, SOX2 and OLIG2 binding sites are enriched for the cognate motifs. However,
SALL2 sites are primarily enriched for SOX motifs (Figure 6C), raising the possibility that
SALL2 is recruited as a complex. Consistently, co-immunoprecipitation experiments
confirmed a direct interaction between SALL2 and SOX2 (Figure S5). Notably, single TF
inductions in DGCs indicate that POU3F2 and SOX2 are each capable of activating subsets
of TPC-specific elements. In contrast, neither OLIG2 nor SALL2 is able to significantly
alter the regulatory landscape of DGCs in isolation (Figure S2). These results suggest that
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the core TFs cooperatively engage TPC-specific regulatory elements to activate gene
expression programs required for GBM propagation.
To comprehensively identify functional targets of the core TFs, we collated a list of genes
within 50 kb of a bound regulatory element and examined their expression by RNA-Seq in
TPCs and DGCs. We identified 325 differentially expressed genes with proximal H3K27ac-
marked elements bound by one or more core TFs. These putative direct targets include all
four core TF genes and 12 of the 19 TPC-specific TF genes (Figure 6D, E and Table S3),
consistent with a role for reciprocal TF interactions in maintaining the TPC regulatory
program.
Co-repressor subunit RCOR2 can replace OLIG2 in reprogramming cocktail
We next focused on target genes of the core TFs that are active in TPCs and iTPCs, but not
in partially reprogrammed 3TF DGCs, reasoning that these might represent critical nodes for
the stem-like GBM cells (see Materials and Methods; Table S4). One nuclear factor
satisfying these criteria is the ASCL1 TF, which we previously found to be an essential
regulator of Wnt signaling in TPCs (Rheinbay et al., 2013). A second is RCOR2, a co-
repressor with essential functions in embryonic stem cells (Yang et al., 2011). RCOR2
resides in a complex with PHF21B and the histone methyltransferase LSD1, both of which
were also identified as putative core TF targets (Shi et al., 2005; Yang et al., 2011). LSD1,
PHF21B and RCOR2 are differentially expressed in TPC and DGC, with the latter
undetectable at mRNA and protein levels in DGCs (Figure 7A, B). We also confirmed a
robust physical interaction between RCOR2 and LSD1 in TPCs (Figure 7C).
Prior studies have suggested that RCOR2 is predominantly expressed in embryonic stem
cells, where it plays a role in sustaining pluripotency. Although RCOR2 has not been
implicated in GBM, we hypothesized that it might play a key role in initiation and
maintenance of TPCs. Since RCOR2 is downstream of OLIG2 in our network, we asked
whether it could substitute for OLIG2 in the reprogramming cocktail. We repeated the DGC
reprogramming and found that DGCs expressing POU3F2, SOX2, SALL2 and RCOR2
could initiate tumor in 100% of cases, indicating that RCOR2 can replace OLIG2 and
establishing it as a key effector of the TPC regulatory program (Figure 7D–F).
Having established a critical role for RCOR2, we next asked whether LSD1, an enzymatic
subunit of the RCOR2 complex, might also be essential. We performed shRNA knock-down
of LSD1 in TPCs and DGCs, confirming >80% reduction in LSD1 mRNA levels in both
cases (Figure S3). Although the proliferation and viability of DGCs were unaffected by the
knockdown, the TPC phenotype was profoundly altered, with marked reductions in cell
survival and near complete loss of self-renewal in serial sphere formation assays (Figure
7G–I). LSD1 knockdown also caused TPCs to lose their capacity to initiate tumors in vivo
(Figure 7K). We also treated TPCs, DGCs and normal human astrocytes with increasing
concentrations of the synthetic LSD1 inhibitor S2101 (Mimasu et al., 2010). TPCs lose
viability in the presence of 20uM inhibitor, while the DGCs and astrocytes are unaffected
(Figure 7J). These findings identify the RCOR2/LSD1 histone demethylase complex as a
candidate therapeutic target in stem-like tumor propagating cells in human GBM.
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Discussion
Hierarchies of cellular differentiation and the associated epigenetic mechanisms – long the
domain of developmental biology – are increasingly appreciated to play critical roles in
cancer. Pioneering work in leukemia led to the identification of stem-like cells with high
tumor propagating potential that give rise to differentiated progeny bearing identical genetic
mutations, knowledge that led to the successful application of differentiation therapy (Ito et
al., 2008; Wang and Dick, 2005). Recent studies have established analogous hierarchies in
certain solid tumors, including glioblastoma, and thus point to the importance of
understanding the epigenetic identities and susceptibilities of such aggressive
subpopulations (Binda et al., 2012; Day et al., 2013; Friedmann-Morvinski et al., 2012; Kim
et al., 2013; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009; Suva et al., 2013).
Here, we identified epigenetic determinants that distinguish an established model of stem-
like TPCs in GBM from their differentiated progeny, which normally are unable to reacquire
stem-like properties. TFs, regulatory elements and interactions critical for the TPC state
were predicted by integrating chromatin maps, RNA expression and TF binding profiles.
Four core TFs were found to be sufficient to reprogram differentiated GBM cells into iTPCs
that faithfully recapitulate in vitro and in vivo properties of TPCs established directly from
human tumors. While SOX2 and OLIG2 have been previously described in GBM, SALL2
and POU3F2 are novel transcriptional regulators in the context of this disease.
All four factors co-bind large numbers of distal regulatory elements with specific activity in
TPCs. SOX2 and POU3F2 can each partially reprogram the epigenetic landscape of DGCs
on their own, consistent with their partial ability to induce spherogenic growth, and their
established roles in direct conversion to neural lineages (Lodato et al., 2013; Lujan et al.,
2012; Pang et al., 2011). Furthermore, SALL2 and SOX2 collaborate through a direct
physical interaction that has not been previously described. The pervasive regulatory
interactions of these neurodevelopmental factors and their efficacy in GBM reprogramming
suggest that the malignant hierarchy maintains key features of normal developmental
processes.
A limitation of our study is that in vitro TPC and DGC models do not fully recapitulate the
diversity of cellular states within primary human GBMs. Nor does our work establish
whether retrograde dedifferentiation can actually occur in primary tumors. Nonetheless, the
clinical relevance of our findings is supported by (i) the identification of stem-like cells that
coordinately express all four factors in primary GBM tumors; (ii) confirmation that large
numbers of TPC-specific regulatory elements are active in primary tumors; and (iii) the
requirement of all four factors for in vivo tumorigenicity in xenotransplanted mice. Given
their demonstrated functionality, the core TFs may have specific advantages for enriching
aggressive cellular subsets relative to conventional surface markers that have been defined
empirically and remain controversial. This may be most apt in IDH1 wild-type proneural
tumors, which account for roughly a quarter of human GBMs and are best represented by
our cellular models.
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In considering therapeutic opportunities presented by the TPC regulatory program, we
focused on potential targets downstream of the core TF network. We identified the RCOR2-
LSD1 complex as a key effector of the TPC regulatory program. RCOR2 can substitute for
OLIG2 in the reprogramming cocktail, while LSD1 suppression triggered cell death
exclusively in TPCs. This vulnerability is consistent with an established requirement for
LSD1 in MLL-AF9 leukemia stem cells (Harris et al., 2012). Thus, dissection of the
epigenetic circuitry governing a malignant hierarchy may guide therapeutic strategies for
targeting cancer stem cells.
In conclusion, we have elucidated epigenetic fingerprints of key subpopulations within the
cellular hierarchy of GBM, identified core TFs that direct the hierarchy and control tumor-
propagating potential, and established a histone demethylase complex as a candidate
therapeutic target in stem-like tumor cells. Although the specific tumor model characterized
here conforms to a unidirectional hierarchy, our reprogramming experiment suggests a
mechanism by which bidirectional plasticity may occur in certain clinical contexts. Further
studies will be needed to assess translational opportunities in GBM and to evaluate the
relative merits of hierarchical and plasticity-based cellular models across the diverse
spectrum of human malignancies.
Experimental Procedures
Cell Culture
Surgically removed GBM specimens were collected at Massachusetts General Hospital with
approval by the Institutional Review Board (IRB protocol 2005-P-001609/16). Tissue was
processed as previously described (Rheinbay et al., 2013). See also supplemental methods.
Flow cytometry and Immunofluorescence
CD133/1-PE or CD133/2-APC (Miltenyi Biotec) and SSEA-1-FITC (BD Biosciences)
antibodies were used according to manufacturer’s instructions. For TF staining in primary
tumors, single cell suspensions were depleted for CD45-positive cells using a MACS
separator (Miltenyi Biotec). Antibodies to SOX2 (R&D Systems), POU3F2 (Epitomics),
SALL2 (Bethyl) and OLIG2 (R&D Systems) were directly conjugated to fluorophores using
Alexa Fluor Conjugation Kits (Invitrogen) or DyLight conjugation kits (Pierce). The CD45-
negative fraction was stained with CD133-PE or CD133-APC prior to fixation and
permeabilization according to manufacturer’s protocol using the Transcription Factor Buffer
Set (BD Pharmingen). Single color controls for all fluorophores were used for
compensation. Flow cytometric analysis was conducted with an LSR II flow cytometer (BD
Biosciences) and analysis was performed with FlowJo software (Treestar). See also
supplemental methods.
ChIP-Seq Assay and 3′end RNA-Seq
ChIP-seq assays were carried out on approximately 1 × 106 cells per histone modification
and 107 cells per transcription factor, following the procedures outlined in (Ku et al., 2008;
Mikkelsen et al., 2007). For primary GBM, cells were dissociated into single cell suspension
followed by depletion for CD45+ inflammatory infiltrate as outlined in previous methods.
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Immunoprecipitation was performed using antibodies against H3K27ac (Active Motif),
POU3F2 (Epitomics), SOX2 (R&D), SALL2 (Bethyl), and OLIG2 (R&D). ChIP DNA
samples were made into libraries for sequencing on the Illumina HiSeq 2000 or 2500
following standard procedures. See supplemental methods for ChIP-seq data processing and
regulatory network reconstruction. ChIP-Seq data are available for viewing at http://
www.broadinstitute.org/epigenomics/dataportal/clonePortals/Suva_Cell_2014.html. For
3′end RNA-seq, total RNA was isolated from cells using the RNeasy Kit (Qiagen). We used
2 ug of total RNA to fragment and polyA isolate the 3′ends of mRNAs. Illumina sequencing
libraries were constructed and subjected to high-throughput sequencing. A processing
pipeline incorporating Scripture (http://www.broadinstitute.org/software/scripture/) was
used to reconstruct the transcriptome and calculate gene expression values as previously
described (Mendenhall et al., 2013; Yoon and Brem, 2010). Data accompanying this paper is
available through GEO under GSE54792. See also supplemental methods.
Generation of H3K27ac consensus sets
H3K27ac sites shared between 4, 6, 8 TPCs and corresponding DGCs were defined as those
that were present in each of the six ChIP-Seq experiments. TPC-specific sites were required
to be present in all three TPC lines and not in any of the DGC lines, and accordingly, DGC-
specific sites were required to be present in all DGC but not in any of the TPC lines. For
heatmaps, H3K27ac or TF signal in a 10kb region for each site was obtained. Total signal
was thresholded at the 95th (H3K27ac) or 99th (TFs) percentile and scaled to values between
0 and 1. See also supplemental methods for H3K27ac-based cell type clustering.
Generation of TF list for experimental testing and motif analyses
TFs from the “CSC” and “stem-cell” sets from Rheinbay et al, 2013 were included in the
testing set. TFs were then filtered for fold difference between TPCs and DGC, and only
those at least 1.5-fold overexpressed in TPC relative to DGC were kept for further analysis.
See also supplemental methods.
Knockdown and overexpression experiments
For knockdown experiments, the following lentiviral shRNA set from Thermoscientific
were used: POU3F2 (RMM4532-NM_005604), OLIG2 (RHS4531-NM_005806), SALL2
(RHS4531-NM_005407), LSD1 (RHS4531-EG23028). Lentiviruses were produced as
previously described (Rheinbay et al., 2013). GBM TPC were selected using 2ug/ml
puromycin for 5 days. GBM non-TPC were selected using 1ug/ml puromycin for 5 days.
After selection, RNA was extracted (Qiagen RNeasy kit) following manufacturer’s
instructions. See also supplemental methods.
Single-cell sphere-formation assay and BrdU
For each condition (shRNA of TFs in GBM TPC or cDNA overexpression in DGC), single
cells were plated in 150ul of serum-free medium in a 96 well plate. Sphere number/96 well
plate was assessed after 2 weeks. The mean and standard deviation of 2 biological replicates
was calculated. In serial sphere forming assays, the same procedure was repeated for 2
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additional passages. BrdU assays were performed following manufacturer’s
recommendations (Roche).
Chemical inhibition of LSD1
TPCs, DGCs and normal human astrocytes were plated 24 hours prior to addition of the
LSD1 inhibitor S2101 (Millipore/Calbiochem). The untreated controls for each cell type
received DMSO as vehicle. Dilution series ranged from 0–100 μM. Media and inhibitor
were refreshed every 96 hours for a 14-day duration. Percent viability was determined by
Trypan blue staining.
Tumorigenicity study
Intracranial injections were performed with a stereotactic apparatus (Kopf Instruments) at
coordinates 2.2mm lateral relative to Bregma point and 2.5mm deep from dura mater. Four
severe combined immunodeficient (SCID) mice (NCI Frederick) were used per condition.
For cDNA overexpression experiments, 100,000 cells were used per mouse, unless
otherwise specified. For shRNA experiments, 5000 TPC cells per mouse were injected.
Kaplan-Meier curves and statistical significance (log-rank test) were calculated with the R
survival package (R, 2008). Animal experiments were approved by the Institutional Animals
Care and Use Committee (IACUC) at Massachusetts General Hospital.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
In glioblastoma, a subset of stem-like cells drive tumor propagation and resistance to
existing therapies, but remain poorly understood. Suvà et al integrate chromatin profiling
and cellular reprogramming to identify a minimal core of neurodevelopmental
transcription factors that is sufficient to generate stem-like cells in glioblastoma. The
corresponding regulatory network identifies tumor dependencies and suggests alternative
approaches to eradicate tumor propagating cells.
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Highlights
• distinct epigenetic state enables glioblastoma cells to propagate tumors in vivo
• four TFs reprogram differentiated glioblastoma cells into tumor-propagating
cells
• these four TFs coordinately expressed in stem-like cells in primary human
tumors
• LSD1 histone demethylase identified as therapeutic target in tumor-propagating
cells
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Figure 1. Epigenetic landscapes distinguish functionally distinct GBM models
(A) GBM cells (MGG8) grown as gliomaspheres in serum-free conditions propagate tumor in vivo while serum-differentiated
cells fail to do so. (B) Flow cytometry of MGG8 TPCs shows positivity for the GBM stemlike markers SSEA-1 and CD133,
while serum-differentiated cells do not. (C) Cells grow in serum as adherent monolayers and express the differentiation markers
GFAP (astroglial), beta III tubulin (neuronal), MAP-2 (neuronal) and GalC (oligodendroglial). (D) Xenografted tumors from
MGG8 TPCs (left) are invasive, crossing the corpus callosum (boxed region), infiltrating along white matter tracks (arrowhead).
At high magnification, the cells are atypical and mitotic figures are evident (arrow). Xenografted tumors from MGG4 TPCs
(right) are more circumscribed but also infiltrate adjacent parenchyma (boxed region, arrowhead). At high magnification areas
of necrosis (*) and mitotic figures (arrow) are readily identified. LV: lateral ventricle. (E) TPC-specific, DGC-specific and
shared regulatory elements. Shared elements tend to be located proximal to promoters, while the vast majority of TPC- and
DGC-specific elements are distal. Motif analyses predict binding sites for TF families within each set of sites. See also
Supplemental FigureS1.
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Figure 2. Candidate regulators for the specification of alternate epigenetic states in GBM
(A) A set of 19 TPC-specific TFs is identified based on RNA-Seq expression and promoter H3K27ac signals in TPCs and
DGCs. TF family is indicated at right. (B) Western blots confirm exclusive protein expression in TPCs for selected TFs. Lower
panel indicates tubulin loading control. (C) ChIP-Seq tracks show H3K27ac signals for loci encoding TPC-specific TFs OLIG1,
OLIG2 and SOX2, or (D) the differentiation factor BMP4 in the respective GBM models. TPC-specific TF loci are enriched for
TPC-specific regulatory elements.
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Figure 3. A core TF network for tumor-propagating GBM cells
(A) Data points indicate percentage of single-cell DGCs capable of forming spheres in serum-free conditions. Each of the 19
TFs in Figure 2A was tested alone (first column, ‘single TF’), in combination with POU3F2 (second column) or in combination
with POU3F2 and SOX2 (third column). HLH family TFs were also tested in combination with POU3F2, SOX2 and SALL2
(fourth column), based on an enrichment of HLH motifs in regulatory elements that failed to activate in 3TF-induced DGCs. TF
combinations that enhanced in vitro spherogenicity (blue) were selected for in vivo testing. (B) Flow cytometry profiles show
expression of the stem cell marker CD133 for DGCs induced by the single, double, triple and quadruple TF combinations with
the highest in vitro sphere-forming potential. (C) For TF combinations with in vitro spherogenic potential (blue in panel 3A),
100,000 cells were injected in the brain parenchyma (n=4 mice per TF combination). Survival curve is shown for this in vivo
tumor-propagation assay. Only the quadruple TF combination POU3F2+SOX2+SALL2+OLIG2 initiated tumors in mice. (D)
Tumor histopathology shows characteristic features of glioblastoma, including necrotic areas (*) and crossing of corpus
callosum (boxed area). At high magnification cells show atypical features and mitotic figures are evident (arrows). LV: lateral
ventricle. (E) Secondary TPC sphere cultures (“iTPC”) derived from xenotransplant tumors express the stem-cell marker
CD133. (F) Contrast field image of iTPC spheres. (G) Left: bar graph shows iTPC and TPC proliferation rates measure by BrdU
incorporation. Right: data points indicate percentage of single cells capable of serial sphere formation in three consecutive
passages in serum-free conditions. Self-renewal properties and proliferation of iTPCs are comparable to corresponding TPCs.
(H) Orthotopic serial xenotransplantation in limiting dilution shows that as few as 50 MGG8 iTPC are sufficient to initiate
tumors. (I) Data points indicate in vitro sphere formation of MGG4 TPCs infected with lentivirus containing shRNA for
POU3F2, OLIG2 or SALL2, compared to control (two hairpins per TF). (J) Survival curve depicts in vivo tumor propagating
potential of MGG4 TPCs infected with POU3F2 shRNA, SALL2 shRNA, OLIG2 shRNA or control shRNA. See also
Supplemental FiguresS2–S4.
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Figure 4. Core TFs reprogram the epigenetic landscape of DGCs
(A) Left: heatmap depicts H3K27ac signals for TPC-specific, DGC-specific or shared regulatory elements defined in Figure 1E.
Relative to control vector infected DGCs, iTPCs gain H3K27ac over TPC-specific elements and lose H3K27ac over DGC-
specific elements, consistent with genome-wide reprogramming of the epigenetic landscape. Right: pie charts show fraction of
regulatory elements (dark cyan) in each set with H3K27ac in iTPC. (B) RNA-Seq expression and promoter H3K27ac levels at
promoter are shown for TPC-specific TFs defined in Figure 2A (NES: Nestin). (C) Hierarchical clustering of MGG8 DGCs,
TPCs and replicate iTPCs (iTPC1/2) by H3K27ac ChIP-Seq signal. (D) RNA-Seq tracks show that core TF mRNAs in iTPCs
include 3′UTRs (shaded in gray). This indicates the endogenous loci are reactivated in iTPCs as the exogenous vectors lack
3′UTRs. (E) H3K27ac signal tracks for loci encoding core TFs show that endogenous regulatory elements (highlighted with
grey shading) are reactivated in iTPCs. (F) Serum-induced differentiation leads iTPCs to convert to an adherent phenotype, up-
regulate differentiation markers GFAP, beta III tubulin, MAP-2, GalC and (G) to lose CD133 expression. (H) Western blots
confirm serum-induced differentiation of iTPCs leads to down-regulation of core TFs. Lower panels: tubulin loading control.
These data indicate that the core TFs can reprogram DGCs into stem-like GBM cells, which have an epigenetic landscape
similar to TPCs that is sustained by endogenous regulatory programs. See also Supplemental Figures S2.
Suvà et al. Page 21
Cell. Author manuscript; available in PMC 2015 April 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. All four core TFs are coordinately expressed in a subset of primary GBM cells with stem-like markers
(A) Quadruple immunofluorescence for core TFs in three human GBM samples shows co-expression in a subset of cells; shown
at right are the fractions of SOX2+ cells that express each other individual TF or all four TFs in each tumor. (B) Flow cytometry
analysis from acutely resected GBM tumors. A majority of cells positive for the four core TFs express the stem-cell marker
CD133. Enrichment is significantly greater than for SOX2-expressing cells. (C) Heatmap shows H3K27ac signal from three
freshly resected GBM tumors for regulatory elements defined in Figure 1E. Right: pie-charts show fraction of regulatory
elements (dark cyan) in each set with H3K27ac. TPC-specific elements show significant enrichment, consistent with a TPC-like
regulatory program in a subset of cells.
Suvà et al. Page 22
Cell. Author manuscript; available in PMC 2015 April 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. TF network reconstruction and targeting
(A) ChIP-Seq signal for core TFs profiled in TPCs (MGG8) shows preferential binding at TPC-specific regulatory elements. (B)
Pie charts indicate proportion of TF binding sites that coincide with the indicated sets of regulatory elements. (C) Sequence
motifs identified in TF ChIP-Seq peaks. With the exception of SALL2 (see text and Figure S5), motifs correspond to the
expected class of TFs, further validating ChIP-Seq experiments. (D) Model for core TF regulatory interactions reconstructed
from binding profiles and expression data (see text and methods). Other TFs defined in figure 2A (green) and chromatin
regulators (red) are highlighted. (E) Signal tracks depict core TF binding over TPC-specific regulatory elements within loci
containing the corresponding TF genes. See also Supplemental Figure S5.
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Figure 7. The LSD1-RCOR2 chromatin complex is essential for GBM TPCs
(A) Plots depict LSD1 and RCOR2 RNA-Seq expression values for TPCs and DGCs. (B) Western blot for RCOR2 (MGG8
TPC and DGC lysates) confirms exclusive expression in TPC. (C) Western blot for LSD1 on RCOR2 immunoprecipitate
indicates co-association between the two proteins in TPCs. (D) Signal tracks depict TF binding and H3K27ac enrichment in the
RCOR2 locus. OLIG2 binds a TPC-specific regulatory element in the locus. (E) Survival curve of mice injected with DGCs
induced with the combination of POU3F2+SOX2+SALL2+RCOR2 indicates that RCOR2 can substitute for OLIG2 in the
cocktail. (F) Coronal section of a xenografted GBM tumor (dashed line) established from iTPCs reprogrammed with the
POU3F2+SOX2+SALL2+RCOR2 combination. (G) Representative images of TPCs and DGCs infected with LSD1 shRNA
show reduced viability specifically in the TPCs. (H) Bar graphs depict percent viability for MGG4 TPCs or DGCs infected with
control shRNA or two different LSD1 shRNAs. LSD1-depletion causes decreased viability in TPCs and has effect on DGCs. (I)
Data points indicate in vitro sphere formation of MGG4 TPCs infected with lentivirus shRNA for LSD1 (two hairpins),
compared to control in three serial passages. (J) Graph depicts percent viability for TPCs and DGCs (MGG4 and MGG8) and
primary astrocytes (NHA) exposed to increasing doses of the synthetic LSD1 inhibitor S2101. A representative image of TPCs
exposed to 20uM S2101 for 96 hours is shown below. (K) Survival curve depicts in vivo tumor propagating potential of MGG4
TPCs infected with LSD1 shRNA (two hairpins) or control shRNA. These data suggest that the RCOR2/LSD1 complex is
essential for stem-like TPCs, and thus represents a candidate therapeutic target for eliminating this aggressive GBM sub-
population. See also Supplemental Figure S4.
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